

**NOT RATED****ACCENTURE**

| IT Services

| 21 March 2025

## Significant deceleration on the cards. Unsure if worst is over

- YoY organic growth is expected to decelerate from ~4.5% in 2QFY25 to 0.5% in 4Q. Implies a US\$2.6bn annualized organic revenue loss
- New guide factors loss of business due to DOGE in US government (8% of revenue) and weakness in the rest due to higher uncertainty
- Expect Infosys/HCLT to guide revenue growth of low-mid-single digits for FY26. 2 months back consensus was at mid-high single digits

**Girish Pai**

research@bobcaps.in

**Significant deceleration guided:** Optically the rise in organic revenue growth guidance for FY25 (Aug YE) by 50bps at the mid-point to 3% compared to 2.5%, given 3 months ago, seems positive. However, the math based on the performance in 1H and 3Q guidance midpoint and the inorganic growth distribution between the 2 halves (400bps in 1H and 200bps in 2H) indicates that YoY organic growth is going to decelerate from ~4.5% in 2QFY25 to 0.5% in 4QFY25.

**Growth in FY26 will at best be equal to that in FY25:** As indicated in our recent note, 'FY26 unlikely to be better than FY25' ([Update](#)) we believe the uncertainty around the Trump 2.0 policies (Tariffs, DOGE and immigration) will impact spending sentiment.

**'Detox' could hit US government spending:** While Tariffs have hogged news headlines, we believe the fiscal spending compression that is likely based on statement of the US treasury secretary where he talked about US having to go through a 'detox' implies that there could be pain not just in 2025 but also beyond.

**Considerable fiscal tightening likely:** Currently the annualized run rate of US fiscal deficit (based on 5 months of FY25 till February) is at USD2.75trn. With the budgeted number at USD1.9trn, there is considerable fiscal tightening on the cards in the next 7 months of FY25 (which will take fiscal deficit as % of GDP to ~6.5%).

## Read through for the Indian companies - Negative

- While Indian services providers do not have much of direct exposure to the US government IT and ITES business, there could be second order impact. This could also lead to Accenture also going after the non-US government business in a more aggressive fashion negatively impacting Indian peers.
- With Accenture talking about elevated level of uncertainty we expect Indian players like Infosys and HCLT to guide towards a CC revenue growth of low to mid-single digits for FY26 compared to the mid to high single digit expectations that the market had two months back (we were not in that camp due to macro and sector specific reasons). With the kind of competitive demand environment expect EBIT margins to be flattish at best during FY26.



### DOGE and Uncertainty hits growth

- The front-loaded growth for FY25 has come from extremely strong order booking in FY24 of ~USD81bn (up 12% YoY).
- The US government business, which constitutes 8% of revenue and USD5.2bn in size may see pressure due to DOGE where cost cutters are going after consulting firms. There could be both volume and pricing pressure here.
- While the commentary around the demand environment was cautious with the CEO pointing to uncertainty, it did not seem to have impacted 2Q very much. Trump 2.0 started at the midpoint of 2Q.
- There could be both first order and second order impact as US tries to structurally set things right on the economic front.
- While we had argued in our research note that Accenture would lower its guidance in our note, due to a strong 1H, it has been able to avoid that.
- This weaker government spending has already been felt by US airlines which have lowered their financial guidance recently due to lower US government travel and also due to lower consumer spending.
- The spending 'detox' could continue in the upcoming years too as Trump 2.0 wants the fiscal deficit to reduce to a sustainable level of ~3%. We are not sure if this would be evenly spread out or front loaded. So even if the Tariff situation gets sorted out, the fiscal tightening is something to contend with.

### Quarter and analyst call highlights

- Accenture reported a strong performance in 2QFY25, with revenue of US\$16.7 bn, growing 8.5% in local currency, at the top end of the guided range.
- Consulting revenues were US\$8.3 bn, up 3% in USD and 6% in local currency.
- Managed services revenues were US\$8.4 bn, up 8% in USD and 11% in local currency, driven by double-digit growth in technology-managed services (including application and infrastructure services) and high single-digit growth in operations.
- In the Americas, revenues grew 11% in local currency, led by banking, capital markets, industrial, health, consumer goods, retail, and travel services, with growth driven by the United States.
- In EMEA, revenues grew 8% in local currency, driven by public service, life sciences, consumer goods, retail, and travel services, with growth led by the United Kingdom.
- In Asia-Pacific, revenues grew 1% in local currency, driven by growth in insurance and utilities, partially offset by declines in chemicals and natural resources. Japan led growth, while Singapore saw a decline.
- The company achieved bookings of US\$20.9 bn, including 32 clients with quarterly bookings greater than US\$100mn.

- Accenture says that it continued to gain market share on a rolling four-quarter basis compared to competitors in the global publicly traded market.
- In Gen AI, Accenture reached a milestone with US\$1.4 bn in new bookings and approximately US\$600mn in revenue during the quarter.
- The operating margin for the quarter was 13.5%, which decreased by 20 bps compared to the adjusted 2QFY24 results.
- In the first half of the year, Accenture invested nearly US\$500mn, primarily through 11 acquisitions.
- New bookings for the quarter were US\$20.9 bn, a 3% decrease in USD and flat in local currency, with a book-to-bill ratio of 1.3. Consulting bookings were US\$10.5 bn with a book-to-bill ratio of 1.3. Managed services bookings were US\$10.4 bn with a book-to-bill ratio of 1.2.
- Accenture increased its data and AI workforce to about 72,000, progressing toward its goal of 80,000 by the end of FY 2026.
- Federal business represented approximately 8% of global revenue and 16% of Americas revenue in FY24.
- The new administration's goal to run the Federal government more efficiently has led to slowed procurement actions, negatively impacting sales in the federal sector.
- The General Services Administration recently instructed all federal agencies to review contracts with the top 10 highest-paid consulting firms contracting with the US government, which includes Accenture Federal Services.
- The GSA's guidance could potentially terminate contracts deemed non-mission critical by the relevant federal agencies, which could impact federal business.
- Accenture continues to believe its work with federal clients is mission-critical, though ongoing uncertainty is expected as the government's priorities evolve, and assessments are conducted.
- Accenture anticipates major opportunities in the long term to help consolidate, modernize, and reinvent the federal government, improving efficiency.
- Recently, global economic and geopolitical uncertainty has increased, marking a shift from the 1Q FY25 earnings report in December.
- Despite the uncertainty, Accenture remains confident in the fundamentals of the industry and its positioning with clients, particularly due to the continued trend of reinvention through technology, data, and AI.


### Guidance

- For 3Q FY25, Accenture expects revenues to be in the range of US\$16.9 bn to US\$17.5 bn, reflecting a 3% to 7% growth in local currency.
- Accenture expects full FY25 revenue growth of 5% to 7% in local currency. This was an increase over the 4-7% given last quarter. The inorganic contribution of

more than 3%, with about 4% in the first half and approximately 2% in the second half of the year.


- Accenture plans to invest US\$2 bn to US\$3 bn in acquisitions during FY25.
- Operating margin for FY25 is expected to be in the range of 15.6% to 15.7%, reflecting a 10 bps to 20 bps expansion over the adjusted FY24 results.
- Regarding 92% of the business outside of US Federal government, Accenture has not seen any pauses in client activity or new initiatives at this time. There have been ongoing discussions with clients, some of which are about accelerating programs, especially in cost-related areas. While there is caution in the market, Accenture has not observed any tangible signs of clients halting activities or pausing projects.
- In 2QFY25, gross margins decreased due to higher subcontractor costs and the impact of business optimization actions, which reduced severance costs compared to 2QFY24. Operating margins are expected to expand by 10 bps to 20 bps for FY25, while the company continues to invest significantly in business and people.
- As the company entered FY25, there was no meaningful increase in budgets for services, with budgets being relatively consistent with prior periods. While it's still early in the year and many clients are still processing recent developments, some clients are reprioritizing initiatives, potentially accelerating cost-cutting efforts over other priorities.
- Discretionary spending in 2QFY25 remained consistent with previous periods, with overall spending still constrained. The guidance for the full year assumes that discretionary spend does not need to improve at the top end of the range, but it also accounts for the possibility of further deterioration at the bottom end of the range.
- Pricing was described as relatively stable, but the market remains highly competitive.
- There has been no recent slowdown in the last few weeks, but there has been elevated uncertainty globally. Key themes influencing this uncertainty include tariffs (a global concern) and consumer sentiment (mainly in the Americas).
- In Europe, major spending announcements, particularly in defense, provide opportunities, with the company well-positioned due to investments and acquisitions. In the UK, recent investments in acquisitions and the use of data and AI are contributing to strong revenue growth.
- In the Americas, especially in federal work, the focus on consolidating, modernizing, and reinventing the federal government presents significant opportunities, with the company leveraging its expertise from decades of work in the sector.
- In H1FY25, the company generated \$1.1bn in revenue from its Gen AI offerings. This is a significant increase compared to \$900mn for the entire FY24.

**Fig 1 – USD YoY Growth Rate**




Source: Company, BOBCAPS Research

**Fig 2 – Local currency YoY Growth Rate**




Source: Company, BOBCAPS Research

**Fig 3 – TTM Order inflow**




Source: Company, BOBCAPS Research

**Fig 4 – Attrition trend**




Source: Company, BOBCAPS Research

**Fig 5 – LC growth of CMT and FS**




Source: Company, BOBCAPS Research

**Fig 6 – Growth trajectory in services lines in LC terms**




Source: Company, BOBCAPS Research

**Fig 7 – Quarterly working capital situation**




Source: Company, BOBCAPS Research

**Fig 8 – ROIC (%)**



Source: Company, BOBCAPS Research

**Fig 9 – 5-year PE multiple chart trajectory**



Source: Company, BOBCAPS Research

**Fig 10 – Key Metrics**

YE 31 Aug (US\$ mn)	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25
Revenue	15,047	16,159	15,424	15,748	15,814	16,565	15,985	16,224	15,800	16,467	16,406	17,690	16,659
Gross Margin	4,524	5,315	4,946	5,186	4,835	5,529	5,182	5,448	4,878	5,498	5,337	5,823	4,975
EBIT	2,062	2,603	2,268	2,593	1,945	2,359	1,913	2,565	2,046	2,631	2,354	2,948	2,245
PAT	1,635	1,786	1,665	1,965	1,524	2,010	1,373	1,973	1,675	1,932	1,684	2,279	1,788
<b>Margins (%)</b>													
Gross Margin	30.1	32.9	32.1	32.9	30.6	33.4	32.4	33.6	30.9	33.4	32.5	32.9	29.9
EBIT Margin	13.7	16.1	14.7	16.5	12.3	14.2	12.0	15.8	13.0	16.0	14.3	16.7	13.5
<b>Vertical Mix (%)</b>													
Communications & High Tech	21.2	21.2	20.0	18.9	18.2	17.4	16.9	16.5	16.8	16.8	16.8	16.2	16.4
Financial Services	19.1	19.1	19.1	18.8	19.0	18.9	18.9	18.7	17.8	17.6	17.5	17.9	18.1
Health & Public Service	17.9	18.1	18.8	19.1	19.1	19.7	20.5	20.8	21.1	21.3	22.0	21.6	21.7
Products	28.8	28.5	29.0	29.6	29.8	30.0	29.7	30.0	30.1	30.3	30.2	30.7	30.3
Resources	13.1	13.2	13.2	13.6	13.8	14.0	13.9	14.1	14.2	14.0	13.5	13.7	13.6
<b>Geography Mix(%)</b>													
Americas	47.0	47.1	48.8	48.4	46.8	46.6	47.3	46.6	46.7	47.6	48.6	49.4	51.3
EMEA	33.3	33.1	31.1	32.2	33.5	33.9	33.1	35.8	35.4	35.1	34.4	36.2	34.8
Asia Pacific	19.7	19.8	20.1	19.4	19.7	19.5	19.6	17.6	17.9	17.3	17.1	14.4	13.8
<b>Services Mix in Revenues(%)</b>													
Consulting	55.3	55.9	54.0	53.6	52.4	52.5	51.3	52.1	50.8	51.4	50.4	51.1	49.7
Managed Services	44.7	44.1	46.0	46.4	47.6	47.5	48.7	47.9	49.2	48.6	49.6	48.9	50.3
<b>Order Inflow (\$bn)</b>													
Consulting	10.9	9.1	8.4	8.1	10.7	8.9	8.5	8.6	10.5	9.3	8.6	9.2	10.5
Managed Services	8.7	7.8	9.9	8.1	11.4	8.3	8.2	9.8	11.1	11.8	11.6	9.5	10.4
Total	19.6	17.0	18.4	16.2	22.1	17.3	16.6	18.5	21.6	21.1	20.1	18.7	20.9
<b>Order Inflow Mix (%)</b>													
Consulting	55.6	53.5	45.7	50.0	48.4	51.8	51.2	46.7	48.7	44.1	42.8	49.2	50.1
Managed Services	44.4	45.9	53.8	50.0	51.6	48.2	49.4	53.3	51.2	55.9	57.7	50.8	49.9
<b>Other Metrics</b>													
Number of employees	698,504	710,432	721,379	737,719	738,143	731,868	732,819	743,041	742,318	750,200	774,303	798,781	801,099
Employee growth YoY (%)	30.1	24.9	15.6	9.4	5.7	3.0	1.6	0.7	0.6	2.5	5.7	7.5	7.9
Net addition of employees	24,179	11,928	10,947	16,340	424	(6,275)	951	10,222	(723)	7,882	24,103	24,478	2,318
Voluntary Attrition (%)	18	20	20	13	12	13	14	11	13	14	14	12	13
Utilisation	92	91	91	91	91	91	91	91	92	92	92	91	91
TCV (US\$bn)	19.6	17.0	18.4	16.2	22.1	17.3	16.6	18.5	21.6	21.1	20.1	18.7	20.9
TTM TCV (US\$bn)	66.8	68.4	71.8	71.2	73.7	74.0	72.2	74.4	73.9	77.7	81.2	81.5	80.8
Growth TTM TCV (YoY %)	23.9	17.3	21.1	12.7	10.4	8.1	0.5	4.5	0.2	5.1	12.5	9.5	9.3
TTM Revenue (US\$bn)	56.7	59.6	61.6	62.4	63.1	63.6	64.1	64.6	64.6	64.5	64.9	66.4	67.2
Book/Bill (TTM)	1.18	1.15	1.17	1.14	1.17	1.16	1.13	1.15	1.14	1.21	1.25	1.23	1.20
Revenue Per Capita (US\$)	87,683	91,750	86,177	86,343	85,722	90,147	87,310	87,945	85,095	88,263	86,091	89,961	83,303
EBIT Per Capita (US\$)	12,014	14,781	12,673	14,218	10,541	12,840	10,448	13,903	11,022	14,102	12,351	14,995	11,224
PAT Per Capita (US\$)	9,527	10,141	9,304	10,774	8,259	10,939	7,499	10,697	9,021	10,357	8,839	11,589	8,941
Average Employees	686,415	704,468	715,906	729,549	737,931	735,006	732,344	737,930	742,680	746,259	762,252	786,542	799,940

Source: Company, BOBCAPS Research



**Fig 11 – QoQ and YoY Growth of various parameters (USD)**

	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25
<b>QoQ Growth</b>													
Overall Revenue (%)	1	7	(5)	2	0	5	(3)	1	(3)	4	(0)	8	(6)
<b>Vertical Wise (%)</b>													
Communications & High Tech	4	7	(10)	(3)	(3)	(0)	(6)	(1)	(1)	4	(0)	4	(4)
Financial Services	(2)	7	(4)	1	1	5	(4)	0	(7)	3	(1)	10	(5)
Health & Public Service	(2)	9	(1)	4	1	8	0	3	(1)	5	3	5	(5)
Products	1	6	(3)	4	1	5	(4)	2	(2)	5	(1)	10	(7)
Resources	1	9	(5)	5	2	6	(4)	2	(2)	3	(4)	9	(7)
<b>Geography Wise (%)</b>													
Americas	2	8	(1)	1	(3)	4	(2)	0	(2)	6	2	10	(2)
EMEA	(2)	7	(10)	6	4	6	(6)	10	(4)	3	(2)	14	(9)
Asia Pacific	0	8	(3)	(1)	2	4	(3)	(9)	(1)	1	(2)	(9)	(10)
<b>Services Wise (%)</b>													
Consulting	(1)	9	(8)	1	(2)	5	(6)	3	(5)	5	(2)	10	(8)
Managed Services	2	6	(0)	3	3	4	(1)	(0)	0	3	2	6	(3)
<b>Growth Rate in Bookings (%)</b>													
New	17	(13)	8	(12)	36	(22)	(4)	11	17	(3)	(5)	(7)	12
Consulting	16	(17)	(8)	(3)	32	(17)	(5)	1	22	(12)	(7)	7	14
Managed Services	18	(10)	27	(18)	41	(27)	(1)	20	13	7	(2)	(18)	10
<b>YoY Growth</b>													
Overall Revenue (%)	24.47	22	15	5	5	3	4	3	0	(1)	3	9	5
<b>Vertical Wise (%)</b>													
Communications & High Tech	29	27	11	(3)	(10)	(16)	(12)	(10)	(8)	(4)	2	7	3
Financial Services	21	19	13	2	5	2	3	2	(6)	(8)	(5)	4	7
Health & Public Service	19	16	15	10	13	12	13	13	10	8	10	13	8
Products	30	25	20	9	9	8	6	4	1	0	4	12	6
Resources	21	21	13	10	11	8	10	7	3	(0)	(0)	6	1
<b>Geography Wise (%)</b>													
Americas	26	23	18	10	5	1	0	(1)	(0)	1	5	15	16
EMEA	24	20	12	(1)	6	5	10	14	6	3	6	10	4
Asia Pacific	22	22	13	3	5	1	1	(6)	(9)	(12)	(11)	(11)	(18)
<b>Services Wise (%)</b>													
Consulting	29	24	14	1	(1)	(4)	(2)	0	(3)	(3)	1	7	3
Managed Services	19	19	16	11	12	10	10	6	3	2	5	11	8
<b>Growth Rate in Bookings (%)</b>													
Total	23	10	23	(3)	13	1	(10)	14	(2)	22	21	1	(3)
Consulting	36	14	5	(14)	(2)	(2)	1	6	(2)	4	1	7	(0)
Managed Services	9	5	39	10	31	7	(17)	21	(3)	42	41	(3)	(6)

Source: Company, BOBCAPS Research

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

## Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited**

Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051**

SEBI Research Analyst Registration No: **INH0000000040 valid till 03 February 2025**

Brand Name: **BOBCAPS**

Trade Name: **www.barodaetrade.com**

CIN: **U65999MH1996GOI098009**



Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

### Recommendation scale: Recommendations and Absolute returns (%) over 12 months

**BUY** – Expected return >+15%

**HOLD** – Expected return from -6% to +15%

**SELL** – Expected return <-6%

**Note:** Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

### Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

### General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time have add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

### Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

#### **Other disclaimers**

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

#### **Distribution into the United Kingdom ("UK"):**

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "MAYBANK"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"); or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

#### **No distribution into the US:**

This report will not be distributed in the US and no US person may rely on this communication.

#### **Other jurisdictions:**

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.